GET THE PICTURE
DIAGNOSING ATTR-CM
Ruling out another type of amyloidosis affecting your heart
Your doctor must rule out another form of cardiac amyloidosis, known as light-chain amyloidosis (AL):
- This is an important step, as AL amyloidosis and ATTR-CM are managed in different ways
- AL amyloidosis is ruled out using blood and urine tests
Diagnostic tests

- A substance called a tracer is injected into your body.
- After 1-3 hours, a special camera takes images of your body
- These images can help your doctor understand if transthyretin (TTR) amyloid fibrils are present in your heart
- Also referred to as a PYP (pyrophosphate) scan
- PYP is not FDA approved for the diagnosis of ATTR-CM. Please consult individual labeling for risks.

- Your cardiologist conducts the biopsy while you are awake
- If amyloid fibrils are found in the removed tissue sample, it is sent out to a lab
- The lab can help determine if they are TTR amyloid strands or not
- Your doctor may also do biopsies from other parts of your body—but a cardiac biopsy is more accurate to detect ATTR-CM
If you are diagnosed with ATTR-CM, genetic testing and counseling is recommended to determine whether you have the wild-type or hereditary type

Genetic Testing
- Will help confirm or rule out the hereditary form of ATTR-CM (hATTR)
- Determines whether family members are at risk, as the mutation that causes hATTR can be passed down
- Usually performed using blood or saliva samples